Vertex Gears Up For Next Generation In CF Therapy
This article was originally published in Scrip
Vertex Pharmaceuticals Inc.'s newest cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) has exceeded Wall Street projections for prescriptions and patient starts, the company reported during its third quarter earnings call Oct. 28.
You may also be interested in...
Moderna Therapeutics LLC extended its dealmaking streak and signaled a shift for its collaborative strategy by signing a partnership with Vertex Pharmaceuticals Inc. to develop a cystic fibrosis (CF) therapy based on the private biotechnology firm's messenger RNA (mRNA)-based drug development technology.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.